Introduction Multidisciplinary studies for glial tumors has produced an enormous amount of information including imaging, histology, and a large cohort of molecular data (i.e. genomics, epigenomics, metabolomics, proteomics, etc.). The big data resources are made possible through open access that offers great potential for new biomarker or therapeutic intervention via deep-learning and/or machine learning for integrated multi-omics analysis. An equally important effort to define the hallmarks of glial tumors will also advance precision neuro-oncology and inform patient-specific therapeutics. This review summarizes past studies regarding tumor classification, hallmarks of cancer, and hypothetical mechanisms. Leveraging on advanced big data approaches and ongoing cross-disciplinary endeavors, this review also discusses how to integrate multiple layers of big data toward the goal of precision medicine. Results In addition to basic research of cancer biology, the results from integrated multi-omics analysis will highlight biological processes and potential candidates as biomarkers or therapeutic targets. Ultimately, these collective resources built upon an armamentarium of accessible data can re-form clinical and molecular data to stratify patient-tailored therapy. Conclusion We envision that a comprehensive understanding of the link between molecular signatures, tumor locations, and patients' history will identify a molecular taxonomy of glial tumors to advance the improvements in early diagnosis, prevention, and treatment.
Hallmarks of glial tumors
Multidisciplinary research highlights the hallmarks of cancer, which constitute a logical framework for mechanistic underpinning of cancer biology and frontier of therapeutics [1] . These hallmarks comprise multiple capabilities acquired during the development of human tumors. In addition to genomic instability [2] , hallmark capabilities include sustaining proliferation [1] , evading growth suppressors and cell death [3] [4] [5] [6] , inducing angiogenesis and immortality [7] , activating invasion and metastasis [8] , promoting inflammation [9] , reprogramming metabolism [10, 11] , as well as escaping immune destruction [12] . Tumor cells often escape immune surveillance while the immune system attempts to constrain tumor growth [13, 14] . The dual host-protective and tumor-promoting actions of immunity are referred to cancer immunoediting [15] . For such, the extrinsic immune pressure either can block tumor development or can facilitate tumor outgrowth by inhibiting host-protective antitumor responses. These hallmark traits are also applied to glial tumors. In glial tumors, a repertoire of normal cells contributes to the acquisition of hallmark traits by providing the tumor microenvironment, which profoundly impact tumor growth and development [16, 17] . Accordingly, tumor heterogeneity is consequently influenced by genetic, epigenetic, and metabolic differences in cancer cells and their interactions with a complex microenvironment [18, 19] . Heterogeneity was thought to arise from distinct mutations in oncogenes as driver. However, heterogeneity persists despite the predominance of single oncogenic driver mutations, perhaps due to the adaptation to tumor microenvironment caused by abnormal vasculature triggering metabolic switches. This heterogeneity has resulted in the stratification of tumors into subtypes, mainly based on cancer-specific genomic or transcriptomic profiles. Although stratification of tumor subtypes can lead to biomarker identification for personalized diagnosis and therapy, stratification alone does not explain the origins of tumor heterogeneity. Moreover, existing subtypes of glial tumors have metabolic and transcriptomic phenotypes that are reminiscent of normal differentiated cells while others reflect the characteristics of stem or mesenchymal cells. Thereafter, emerging studies had raised additional factors to be considered, such as tumor locations, life style, and individual residential history.
Recognition of these evolving hallmark concepts and their applicability to improve the therapy of glial tumors, this review focus on how to integrate a wide range of datasets to tackle issues within heterogeneous glial tumors via big data and shared discoveries. Computational approaches are coming to the fore that allow interrogation of various types of data, in particular providing intelligence on the broad variety of complex associations between tumor cells and multiple factors. The depth and breadth of information obtained is promising for biomarker discovery, potential targets for drug therapies, as well as for clinical trials and patient-tailored treatment plans. Understanding how to obtain relevant information and how best to analyze these overwhelming datasets is critical for future advances in research and cancer treatment.
Advancing neuro-oncology via big data approach

Caveat in molecular classification
The WHO 2016 and TCGA classification systems represent a significant improvement in line with the increased discoveries to date on brain cancer biology [20, 21] . According to the 2016 WHO, gliomas are classified not only by histopathologic appearance but also by molecular parameters [20] [21] [22] [23] [24] [25] . Histological grading alone, such as quantifying proliferation through mitotic counts may vary from tissue artifacts, staining conditions, sampling, or extended time from tissue removal to fixation [24] . Thus, the incorporation of molecular features has significant impact on the classification of astrocytic and oligodendroglial tumors, which are now grouped together as diffuse gliomas according to the growth pattern and isocitrate dehydrogenase (IDH) genetic status. However, the morphological criteria for diffuse gliomas cannot be negated and remains an important factor in WHO's classification. Based on the presence or absence of histological features (i.e. mitotic activity, florid microvascular proliferation, necrosis), diffuse gliomas are graded as WHO grade II (low grade), WHO grade III (anaplastic), or WHO grade IV (GBM) [20, 21] . Yet, there remains groups of tumors that do not fit into the defined tumor types in the WHO 2016 classification, for which are designated as not otherwise specified (NOS), indicating that further study is required for the improvement of classification [25] .
The current WHO classification of high-grade gliomaglioblastoma (GBM) into two groups IDH wildtype/IDH mutant may not be sufficient as there is no clear distinction in therapy for these subtypes [24, 26] . Additionally, the variations in patients with TERT, TP53, ATRX, PTEN mutations and EGFR amplifications in both groups show a lack of a definitive molecular signature. Instead, it may be worthwhile to consider methylation as a classification descriptor based on the widespread effect of aberrant methylation as a result of changes in IDH gene expression and metabolic function. Mutated IDH genes significantly reduce enzymatic activity in the conversion of isocitrate to α-ketoglutarate (αKG) in the tricarboxylic acid (TCA) cycle that consequently produces d-2-hydroxyglutarate (d-2HG) by reducing αKG in an NADPH-dependent manner, also inhibits the enzymatic activity of dioxygenases requiring αKG. This results in epigenetic changes (i.e. aberrant methylation patterns) and altered gene expression that may contribute to the pathogenesis of gliomas.
The Cancer Genomic Atlas (TCGA) has developed a molecular classification of GBM into Proneural, Neural, Classical and Mesenchymal subtypes [27] , based on gene expression or mutation and chromosome loss or translocation in addition to their distinctions in neural cell types. The Proneural class was highly enriched with the oligodendrocytic signature but not the astrocytic signature, while the Classical group was strongly associated with the astrocytic signature. The Neural class had a strong enrichment for genes differentially expressed by neurons in addition to its association with the oligodendrocytic and astrocytic differentiation. The Mesenchymal class was strongly associated with the cultured astroglial signature [27] . The current TCGA classification method with the incorporation of molecular characteristics in addition to histopathological analysis represents a significant improvement towards greater understanding of biological underpinnings of GBM and other tumors in the central nervous system, as well as offers potential application of more targeted therapy. However, the TCGA's classification into the four subtypes may not be representative of the tumor heterogeneity. Using single-cell QPCR and single-cell RNA-seq for the tumors classified by TCGA, a study found multiple subtypes within the tumors that do not fit into TCGA's classification. Thus population data from bulk tumor profiles detected the dominant transcriptional program, but did not capture the diversity of transcriptional subtypes within a tumor [28] . Wang et al., classified three distinct subtypes-mesenchymal (MES), proneural (PN), classical (CL) but none were enriched for the neural (NE) subtype. The NE subtypes has previously been related to the tumor margin where increased normal NE tissue is likely to be detected and such contamination might explain why the NE subtype was the only subtype lack of characteristic gene abnormalities [17] .
To reinforce additional layers of molecular information beyond genomic studies, Haskins et al. studied the abnormal protein expression profile in MRI-classified SVZassociated GBM and found the up-regulation of metabolic enzymes, ribosomal proteins, and heat shock proteins. In addition, markers representing SVZ cells (GFAP and Doublecortin) were highly expressed, supporting the hypothesis that the tumor cells are related to the SVZ cells [29] . Gollapalli et al. expanded the proteomic analysis to delineate the differences in serum and tissues from SVZ + and SVZ− tumors. They found significant alterations of various acute phase proteins and lipid carrying proteins in the serum proteomic analysis while significant changes in cytoskeletal, lipid binding, chaperone and cell cycle regulating proteins in the tissue samples [30] . Perhaps, it can be inferred from these findings to further distinguish WHO grade IV GBM into two subgroups, SVZ-and non-SVZassociated GBM. This concept will be further elaborated in the subsequent subsections: Refinement of Big Data Approach in Imaging and Molecular Interface.
As described in the preceding paragraphs, a caveat is obtaining tissues and sections that accurately reflect the extent and heterogeneity of the tumor is greatly dependent on professional expertise and medical protocol. Also, timeconsuming molecular and histopathological processes may be hindered by regulatory restrictions and technological availability. Perhaps, a streamline process of high-throughput tumor-on-chip using microfluidic device would overcome these obstacles to facilitate the cellular and molecular characterization. Another key hurdle to overcome is the development of tumor resistance to therapy, for which is impeded by the lack of longitudinal molecular data for the same patients with recurrent tumors. Moreover, the molecular classification is confounded with the limitations to detect somatic mutations based on tumor purity and to determine the attraction of non-cancerous cells toward the tumor site (e.g. endogenous neural stem progenitor cells migrate toward tumor cells) and vice versa. Lastly, it is difficult to distinguish tumor-specific versus tumor microenvironment transcriptome. Therefore, further work is needed using single-cell analyses to separate the potential contribution of any resident non-cancerous neural stem or progenitor cells [31] [32] [33] .
Refinement of big data approach in imaging and molecular interface
The brain imaging of tumor location includes structural and functional imaging. The functional imaging techniques detect metabolic changes and lesions on a finer scale as well as visualize brain activities [34] . Structural imaging like MRI consists of different measures related to brain structure, tumor location, injuries and other brain disorders. MRI is a non-invasive procedure widely implemented in existing clinics as it does not require a biopsy of tissue sample or the use of ionizing radiation. To improve patient prognosis and quality of life through precision medicine, imaging characterization and molecular signatures should be incorporated into big data analysis. A conceptual approach through big data integrated analysis covering genomics, epigenomics, metabolomics, proteomics, radiomics, and transcriptomics can be the foundation for designing new studies to identify novel targets and clinical trials ( Fig. 1) .
Machine learning to identify the meaningful features of molecular data
The study by Lin et al. [19] identified commonly upregulated genes in glial tumors across multiple large datasets crucial for cell cycle, chromatin activity, centromere assembly and chromosome segregation. Despite the cause or consequence, this short list could be used as a starting point in the selection of representative features for machine learning. Given the plethora of molecular markers at gene/protein/epigenetics, it could be more useful to focus upon the upstream mechanism or initiators of tumor development as therapeutic targets. It is worth mentioning that comparison between healthy and cancerous conditions is crucial to signify causative mechanism and/or targets. For non-disease related big data, the Encyclopedia of DNA Elements (ENCODE) project provides a rich resource of mapped regions of transcription, transcription factor association, chromatin structure, DNA methylation and histone modification for multiple cell types [35, 36] . Integrating molecular data of brain cancers with ENCODE may uncover significant correlations of epigenetic and gene regulation. Likewise, the computational analysis across various molecular datasets would reveal dysregulated elements in cancer initiation. For example, Xiong et al. used RNAseq data from the Illumina Human Body Map 2.0 project to develop a computational model of splicing regulation by regulatory cis-elements using a Bayesian machine learning algorithm that enabled the prediction and classification of disease-causing variants, independent of population data, genome-wide association studies (GWAS), expression-based quantitative trait loci (QTL), and functional annotations of the genome [37] .
Deep learning for image processing and classification
A study by Nie et al. employed the use of deep learning to automatically extract implicit and high-level features from MRI that are able to predict survival time [38] . This computational approach enabled clinician to obtain radiomics of imaging information without personal subjectivity, bias and interpretation of only obvious features like simple changes in image contrast/intensity. This radiomics of multimodal neuroimages could potentially form the frontline of glioma classification according to tumor locations [38] . Radiomic studies can be extended to link specific tumor biomarkers and tumor location as different regions of the brain are composed of different cell types exposed to environmental signaling factors that ultimately exhibit different molecular characteristics. However, improvements are critically needed in (i) refining radiographic algorithm, (ii) standardizing the equipment, (iii) defining the settings, and (iv) the use of dyes to enhance contrast.
Growing evidence implicated that the tumor cell of origin is located in the neurogenic niche-the subventricular zone (SVZ), which accounts for the stemness and plasticity of glial tumor cells within the highly variable microenvironment [39] [40] [41] [42] . In this regard, a potential follow-up to the study by Nie et al. [38] is to superimpose the location of tumor proximity to the SVZ and the distinct radiomics obtained from deep learning to ascertain if there is any correlation. The resulting image features can then be integrated with the molecular characteristics of corresponding tumor, subsequently subjected to training algorithms for prediction of patient survival times. For the best practice of this deep learning approach to refine the classification of glioma subtypes, some issues must take into concern including the initial selection and optimization of the best imaging features, measuring performance, and avoiding overfitting to data. Thus, it is essential to be multiple iterations to improve the predictions, as well as to compare with other published data on tumor classification models and pivotal molecular signatures obtained from normal human genome (e.g. from ENCODE).
Multi-omics is undergoing big data revolution
While genomics has informed current precision medicine, genetic mutations or altered gene expression alone do not always reflect changes of the corresponding protein as many other factors can contribute to protein modifications and metabolism that influence tumor behavior. It is well known that most tumors have different mutations, making it difficult to determine which are important drivers for potentially druggable targets as opposed to just passengers. To capture the intricate connections between tumor biology and patient outcomes, integrating genomic and proteomic data through proteogenomics may bridge the missing link. Subsequently, a forefront of machine learning to integrate tumor imaging with histology and proteogenomics will refine big data analysis toward precision medicine. For instance, in addition to classifying gliomas into IDH-mutant versus IDH-wildtype, a further breakdown of glioma subtypes can be made through tumor location displayed by advanced imaging technology, followed by profiling molecular signature(s) and implementing histopathological test. Ultimately, with the aid of artificial intelligence, the imaging with greater accuracy of tumor spatial information will link to retrospective multi-omics data and to the endpoint of overall prediction for next generation precision medicine. Fig. 1 Scheme proposes future big data multi-omics integrating multiple layers of information. All of these factors and approaches can be extended beyond the stratification of glial tumors to identify the hallmarks of other brain cancers. Shaded description highlights advanced approaches and technologies to generate new data. Italic font depicts additional factors to be considered and examined in this big data and multidisciplinary approach
Miscellaneous considerations for big data approach
While many cases of low grade gliomas (LGG) may eventually become GBM [43] , it is critical to evaluate how GBM differs from LGG, especially on what distinctive features cause LGGs to have a much better prognosis and lower recurrence rate. For example, a better understanding is needed on whether LGGs originate from GSCs and how these cells differ from GSCs of more aggressive tumors. It is also important to examine how IDH mutation confers increased sensitization of cancer cells to chemotherapy or radiotherapy, and the therapeutic potential by inhibiting wild type IDH to mimic therapy responses of IDH mutant cancers.
The link between GBM and neurodegenerative diseases is another potential area of exploration. Both exhibit similar neurological symptoms which, at least in part, stem from dysregulation in neurogenesis. For such, the neural stem progenitor cells fail to differentiate in both GBM and neurodegenerative diseases while abnormal cell death and aberrant proliferation occurs in neurodegenerative diseases and GBM, respectively. Another similarity between brain tumor and neurodegenerative/neurological diseases is changes in neuronal circuit under different pathological conditions. For instance, tumor infiltration results in reorganization of the functional connectivity networks similar to altered plasticity occurring in stroke and trauma. In addition, tumor progression is associated with glutamate toxicity and seizures, which also occur in neuropsychological disorders [44] . As brain tumors cause altered functional connectivity at not only the tumor site but also other brain regions, intraoperative mapping by awake craniotomy allows maximal safe resection. In addition to preventing the disruption of functional circuits, intraoperative mapping during repeat awake craniotomy unravels the functional plasticity of adult cortex [45] , suggesting that could lead to potential methods for understanding functional restoration [44, 46] . Herein, greater understanding of the underlying neurobiology governing the functional circuit and the lesion-induced plasticity in the brain is important for advancing precision neurooncology [47] . A thorough algorithmic approach will benefit this advancement by analyzing the common signs and symptoms exhibited by patients with brain cancer, and further differentiating from the signs and symptoms shown by other neurological diseases.
Other factors need to take into consideration of the aggressiveness of the tumor are patient overall survival after the standard treatment; whether it is a primary, recurrent, secondary tumor or metastasis; and whether the patient only underwent the standard treatment or had alternative therapies (e.g. immunotherapy). Other aspects to be addressed as risk factors include viral or bacterial infections affecting the nervous system, demographic, as well as the individual dietary habits and life style. It is possible that these risk factors would reflect changes in the immune responses and metabolism, reasoning that identifying circulating tumor markers via blood sample testing will be useful in facilitating early detection of this aggressive cancer prior to MRI or tissue biopsy.
Residential history-the record of an individual's places of residence across lifetime
Compelling evidence recognizes the residential history as part of cancer etiology and outcomes to assess the lasting health impact [48] [49] [50] [51] [52] . Residential history encapsulates a person's interactions with the physical and social environment, such as accessibility to healthcare resources and disparities, physical conditions of housing, neighborhood characteristics, food consumption, as well as environmental exposures to chemicals or contaminants. Given the awareness of increasingly available electronic sources of residential history data, the development of analytical strategies or algorithm is required to capitalize on assessing the interactions between place and cancer over time. This integrated teamwork includes, but is not limited to, epidemiology, statistics, geospatial science, computer science, demography, and behavioral science.
Early-life factors in cancer development later
Given that considerable evidence indicates a potential role for early-life exposures in cancer development, it is necessary to better understand how early-life factors mediate biological processes relevant to carcinogenesis covering stages of maternal-paternal, in utero, birth and infancy, puberty and adolescence, as well as teenage and young adult years [53] [54] [55] [56] [57] . In addition, based on what happens at early-life, whether predictive markers for cancer risk can be measured for use in cancer prevention strategies. Particularly, markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait years for cancer development. Ultimately, a better mechanistic understanding of how earlylife events and exposures contribute to the etiology of cancer later in life will allow for the development of effective cancer prevention during pregnancy or early life. For instance, economical nutrient quantity and quality represent one of environmental determinants of an individual's health. A formidable process down there is the interaction of nutrition with genetic and epigenetic modifications. Epigenetic modifications do not change the DNA sequence but can influence gene expression and phenotypic variation. This adds another 1 3 layer of complexity when dissecting nutrition related hallmark traits as nutrients can affect epigenetic modifications and subsequently gene expression. To determine how desirable phenotypes were generated and sustained in populations over time, we must explore the relationship between epigenetic mechanisms, environmental exposure, nutrients and phenotypic variation. With the advent of high throughput technologies to explore the molecular effects of early-life factors, we envisage that subsequent big data integration will delineate the role of early-life factors in cancer development.
Conclusion
With respect to multidisciplinary research and evolving hallmarks of cancer, this review unbiasedly summarizes studies related to glial tumor biology. Authors do not attempt to enumerate the developing or ongoing myriad therapies. Instead, we recognize the growing armamentarium of targeted therapeutics can be refined based on one or more hallmark of glial tumors.
In summary of big data approach, interpretation of spatial features by radiomics-based tumor imaging and prognosis by circulating biomarkers will be used as an initial classification for further integrated analysis with multi-omics and all other considered factors. Currently, the existing data format can be divided into structured (omics) and non-structured data (clinical reports). The structured query language (SQL) is used in relational database while unstructured query language (NoSQL) is no schema with little relationship. Unequivocally, integrating all heterogeneous data including imaging, molecular, histological, residential history of patients, and therapeutic responses requires both SQL and NoSQL database. We are unclear as to whether the evolving hallmarks will lead to paradigm shifts in our understanding of the pathogenesis in glial tumor or to elaborate regulatory mechanisms that have been depicted. Looking ahead, we envision significant advances by integral use of big data and machine learning for comprehensive assessment of the prognostic values. Once new or specific molecular targets are acquired as causative elements for the distinct subtypes of gliomas, studies on drug discovery and therapeutic mechanisms can be accelerated through the combination of high throughput biological and bioengineering approaches using tissue-on-chip (i.e. patient-derived brain tumor organoids and microfluidics). Ultimately, the emerging approach through refinement of big data along with multidisciplinary studies can involve co-targeting key biomarkers, implementing lifestyle changes, or eliminating the potential triggers of cancer-causing agents, such as environmental exposures.
